Eli Lilly and Company $LLY Shares Purchased by Gladstone Institutional Advisory LLC

Gladstone Institutional Advisory LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,931 shares of the company’s stock after acquiring an additional 1,727 shares during the quarter. Gladstone Institutional Advisory LLC’s holdings in Eli Lilly and Company were worth $15,970,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of LLY. Sumitomo Mitsui Financial Group Inc. acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $27,000. Evolution Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at $29,000. Steph & Co. increased its position in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares in the last quarter. Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company in the second quarter worth $31,000. Finally, Bare Financial Services Inc raised its holdings in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 4.1%

LLY opened at $1,107.54 on Thursday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market capitalization of $1.05 trillion, a price-to-earnings ratio of 54.18, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The business has a 50-day moving average of $1,028.26 and a two-hundred day moving average of $856.98. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,117.66.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the firm posted $1.18 EPS. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 33.86%.

Analysts Set New Price Targets

LLY has been the topic of a number of analyst reports. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Finally, Daiwa Capital Markets set a $1,230.00 price objective on shares of Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, December 16th. Five investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $1,169.00.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly confirmed it will buy Ventyx Biosciences in an all-cash deal worth about $1.2 billion, gaining a pipeline of oral small-molecule NLRP3 inhibitors and inflammatory disease candidates that expand Lilly beyond diabetes/weight-loss. This acquisition is a clear pipeline/strategic positive. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Positive Sentiment: Lilly expanded its obesity/metabolic pipeline via a multiyear partnership/licensing deal with Nimbus (reported value ~$1.3B), adding an oral obesity candidate to its development portfolio — another growth pathway beyond injectables. Boston biotech Nimbus to partner with Eli Lilly on weight-loss pill in $1.3 billion deal
• Positive Sentiment: Lilly struck a collaboration with InduPro on a next-gen cancer program worth up to $950 million, strengthening oncology exposure and long-term revenue optionality. Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
• Positive Sentiment: Clarivate named several Lilly cardiometabolic launches among drugs to watch for 2026, highlighting continued product catalysts beyond current blockbusters. Lilly’s prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate
• Positive Sentiment: Analysts are bullish: Citigroup flagged ~50% upside, and several upgrades/positive notes have circulated, supporting momentum and investor confidence in Lilly’s pipeline and earnings outlook. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Neutral Sentiment: The stock printed an all-time high intraday as buyers priced in the M&A and deal flow; that’s market confirmation of the reaction but not a new fundamental. Eli Lilly stock hits all-time high of 1113.03 USD
• Negative Sentiment: Lilly faces legal pressure: the Indiana attorney general sued alleging inflated insulin pricing, a regulatory and reputational overhang that could lead to fines, settlements or policy scrutiny. Indiana sues Eli Lilly alleging insulin price-fixing scheme

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.